IGF1 and acromegaly: Nevertheless, the rate of resistance increased up to 60% when we reassessed the acromegaly situation in the last follow-up visit since only 39% of the patients who were initially treated with fgSRL in monotherapy or combination with cabergoline maintained an adequate IGF-1 control with no need for additional therapies.